Literature DB >> 16024170

The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives.

Wendy B London1, Luca Boni, Thorsten Simon, Frank Berthold, Clare Twist, Mary Lou Schmidt, Robert P Castleberry, Katherine K Matthay, Susan L Cohn, Bruno De Bernardi.   

Abstract

Recent evidence suggests that the cut-off for age utilized in neuroblastoma risk groups should be increased from the 365-day cut-off currently in use. Separate cooperative group analyses were performed by German and Italian groups and two analyses by the Children's Oncology Group (North America, Australia, New Zealand, Switzerland, Netherlands). In general, the results are in agreement regarding the prognostic contribution of age. There is strong evidence to support an increase in the age cut-off to a value in the range of 15-18 months based on the results from the German analysis and two COG analyses. However, Italian results in INSS stage 4 patients show that outcome in patients 12-17 months is not better than that of older patients. Further analyses are warrented.

Entities:  

Mesh:

Year:  2005        PMID: 16024170     DOI: 10.1016/j.canlet.2004.12.054

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.

Authors:  Annalisa Pezzolo; Elena Rossi; Stefania Gimelli; Federica Parodi; Francesca Negri; Massimo Conte; Angela Pistorio; Angela Sementa; Vito Pistoia; Orsetta Zuffardi; Claudio Gambini
Journal:  Neuro Oncol       Date:  2008-10-15       Impact factor: 12.300

2.  Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.

Authors:  Julie R Park; Jeffrey R Scott; Clinton F Stewart; Wendy B London; Arlene Naranjo; Victor M Santana; Peter J Shaw; Susan L Cohn; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

3.  Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy).

Authors:  Elisa Dama; Guido Pastore; Maria Luisa Mosso; Milena Maria Maule; Luisa Zuccolo; Corrado Magnani; Franco Merletti
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

4.  Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.

Authors:  Setsuko Kaneko; Miki Ohira; Yohko Nakamura; Eriko Isogai; Akira Nakagawara; Michio Kaneko
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-07       Impact factor: 4.553

5.  Mechanisms of CHD5 Inactivation in neuroblastomas.

Authors:  Hiroshi Koyama; Tiangang Zhuang; Jennifer E Light; Venkatadri Kolla; Mayumi Higashi; Patrick W McGrady; Wendy B London; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2012-01-31       Impact factor: 12.531

6.  A single center clinical analysis of children with neuroblastoma.

Authors:  Jing-Bo Shao; Zheng-Hua Lu; Wen-Yan Huang; Zhi-Bao Lv; Hui Jiang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

7.  Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.

Authors:  Peter E Zage; Morris Kletzel; Kevin Murray; Robert Marcus; Robert Castleberry; Yang Zhang; Wendy B London; Cynthia Kretschmar
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

8.  Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification.

Authors:  Eiso Hiyama; Hiroaki Yamaoka; Satoshi Kondo; Akihiro Yoneda; Tatsuro Tajiri; Masahiro Fukuzawa; Masahiko Sugiyama; Yutaka Hayashi; Fumiaki Sasaki; Megu Ohtaki
Journal:  Pediatr Surg Int       Date:  2007-08-16       Impact factor: 1.827

Review 9.  Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

Authors:  Wendy B London; Rochelle Bagatell; Brenda J Weigel; Elizabeth Fox; Dongjing Guo; Collin Van Ryn; Arlene Naranjo; Julie R Park
Journal:  Cancer       Date:  2017-09-08       Impact factor: 6.860

10.  Neuroblastoma in a 55-year-old patient: a case report.

Authors:  Cornelia Then; Kathleen Ebelt; Alexandra Langer; Doris Mayr; Ralf Schmidmaier; Fuat Oduncu
Journal:  Case Rep Oncol       Date:  2010-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.